Roche Holding AG (ROGZ.XC)
| Previous close | 235.10 |
| Open | 235.20 |
| Bid | 236.90 x 0 |
| Ask | 237.10 x 0 |
| Day's range | 234.00 - 237.70 |
| 52-week range | 213.00 - 293.50 |
| Volume | |
| Avg. volume | 198,400 |
| Market cap | 191.277B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 16.55 |
| EPS (TTM) | 14.31 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 9.60 (4.05%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
Zacks4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Barrons.comDow Hitting 40,000 Is Good but Look Here for Where Markets Are Headed, and 5 Other Things to Know Today.
Reddit content is coming to OpenAI’s chatbot, Roche’s weight-loss drug impresses analysts in early-stage trials, and other news to start your day.
BenzingaRoche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
Thursday, Genentech, a unit of Roche Holdings AG (OTC:RHHBY), released results from the Phase 1b trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes. The study found that a once-weekly subcutaneous injection of CT-388 over 24 weeks resulted in significant weight loss in healthy adults with obesity compared to placebo. The weight loss achieved with CT-388 was clinically meaningful, with a mean placebo-adjusted weight loss of 18.8% (p
